Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370907 | 0.85 | NPBWR1 (0.50) | UCHL1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL22216305 | 0.83 | UCHL1 (0.64) | UCHL1NPC1LMNAMAPTTUBB4A | |
| SCHEMBL23122494 | 0.83 | NPC1 (0.58) | UCHL1NPC1LMNAMAPTTUBB4A | |
| SCHEMBL23122438 | 0.82 | UCHL1 (0.62) | UCHL1NPC1LMNAMAPTTUBB4A | |
| SCHEMBL22206961 | 0.81 | UCHL1 (0.60) | UCHL1NPC1LMNAMAPTTUBB4A | |
| SCHEMBL18387731 | 0.80 | UCHL1 (1.00) | UCHL1NPC1LMNAMAPTTUBB4A | |
| SCHEMBL366891 | 0.80 | UCHL1 (0.46) | UCHL1NPBWR1MCHR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20745892 | 0.79 | NPC1 (0.59) | UCHL1NPC1LMNAMAPTNPBWR1 | |
| SCHEMBL15882564 | 0.79 | KMT2A (0.44) | UCHL1NPC1LMNAMAPTALDH1A1 | |
| SCHEMBL370942 | 0.78 | LMNA (0.80) | UCHL1NPC1LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3800186-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2024-10-02 | — | — | EP | disclosed |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| CN-107849013-B | Cyanopyrrolidines as DUB inhibitors for the treatment of cancer | 特殊治疗有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-111018861-B | Pyrrolopyrimidine compounds | 正大天晴药业集团股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3800186-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | Mission Therapeutics Limited (GB) | 2021-04-07 | — | — | EP | disclosed |
| EP-3235819-B1 | PYRROLOPYRIMIDINE COMPOUNDS USEFUL AS JAK INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2020-11-18 | — | — | EP | disclosed |
| US-20200231542-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2020-07-23 | — | — | US | disclosed |
| US-10669234-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-02 | — | — | US | disclosed |
| US-10669234-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-02 | — | — | US | disclosed |
| CN-111018861-A | Pyrrolopyrimidine compounds | 正大天晴药业集团股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-20180194724-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| EP-3322702-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | Mission Therapeutics Limited (GB) | 2018-05-23 | — | — | EP | disclosed |
| EP-3235819-A1 | PYRROLOPYRIMIDINE COMPOUND | Centaurus BioPharma Co., Ltd. (CN) | 2017-10-25 | — | — | EP | disclosed |
| EP-3235819-A1 | PYRROLOPYRIMIDINE COMPOUND | Centaurus BioPharma Co., Ltd. (CN) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017009650-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-01-19 | — | — | WO | disclosed |
| WO-2017009650-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-01-19 | — | — | WO | disclosed |
| WO-2016095805-A1 | PYRROLOPYRIMIDINE COMPOUND | 北京赛林泰医药技术有限公司 | 2016-06-23 | — | — | WO | disclosed |
| US-20130210809-A1 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | BOLEA CHRISTELLE (CH) | 2013-08-15 | — | — | US | disclosed |
| EP-2595986-A2 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012009009-A2 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669234-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | UCHL1 3/4885NPC1 3497/4885LMNA 3786/4885 |
| US-20180194724-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | USP30, USP39, UCHL1 | UCHL1 3/4885NPC1 3497/4885LMNA 3786/4885 |
| US-20200231542-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | USP30, USP39, UCHL1 | UCHL1 3/4885NPC1 3497/4885LMNA 3786/4885 |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | UCHL1 3/4885NPC1 3497/4885LMNA 3786/4885 |
| US-20130210809-A1 | NOVEL 2-AMINO-4-PYRAZOLYL-THIAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM4, GRM1 | UCHL1 4390/4885NPC1 1289/4885LMNA 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.